CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety
Abstract
Introduction: Dengue virus (DENV) is a serious global health problem. CYD-TDC (Dengvaxia®) was the first vaccine to gain regulatory approval to try and address this problem. Aim: Summarize all available evidence on the immunogenicity, efficacy and safety of the CYD-TDV dengue vaccine. Method: Meta-analysis and systematic review. Results: The best and worst immunogenicity results were for DENV4 and DENV1, respectively. Vaccine efficacy of 60% was derived from studies with participants aged 2–16 years old, with DENV4 and DENV2 presenting the best and worst results, respectively. Erythema and swelling were more frequent with CYD-TDV. No differences were detected for systemic adverse events. Conclusion: CYD-TDV showed moderate efficacy in children and adolescents. From the immunogenicity results in adults, we can expect satisfactory efficacy from vaccination in this population.
Supplementary Material
File (suppl_materials.doc)
- Download
- 86.00 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Bhatt S, Gething PW, Brady OJ et al. The global distribution and burden of dengue. Nature 25, 504–507 (2013).
2.
Brady OJ, Gething PW, Bhatt S et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl. Trop. Dis. 6, e1760 (2012).
3.
Thoisy B, Lacoste V, Germain A et al. Dengue infection in neotropical forest mammals. Vector Borne Zoonotic Dis. 9, 157–169 (2009).
4.
Simmons CP, Farrar JJ, Chau NV, Wills B. Current concepts dengue. N. Engl. J. Med. 366, 1423–1432 (2012).
5.
Godoi IP, Taranto MFR, Lima WG et al. NS2B-NS3pro as a molecular target drugs development against dengue. Biochem. Biotech. Rep. 2, 16–30 (2004).
6.
Costa VG, Marques-Silva AG, Floriano VG, Moreli ML. Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials. Vaccine 32, 4885–4892 (2014).
7.
Tomlinson SM, Malmstrom RD, Watowich SJ. New approaches to structure-based discovery of dengue protease inhibitors. Infect. Disord. Drug Targets 9, 1–17 (2009).
8.
Forshey BM, Stoddard ST, Halsey ES. Direct feeding on dengue patients yields new insights into human to mosquito dengue virus transmission. Future Virol. 8, 1145–1149 (2013).
9.
Yacoub S, Mongkolsapaya J, Screaton G. Recent advances in understanding dengue. F1000Research 78, 1–10 (2016).
10.
Reiter P. Aedes albopictus and the world trade in used tires, 1988–1995: the shape of things to come? J. Am. Mosq. Control Assoc. 14, 83–94 (1998).
11.
Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect. Dis. 16, 935–941 (2016).
12.
Constenia D, Garcia C, Lefcourt N. Assessing the economics of dengue: results from a systematic review of the literature and expert survey. Pharmacoeconomics 33, 1107–1135 (2015).
13.
Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect. Dis. 9, 678–687 (2009).
14.
Durbin AP, Whitehead SS. Next-generation dengue vaccines: novel strategies currently under development. Viruses 3, 800–814 (2011).
15.
Coulange BH, Benabdelmoumen G, Gergely A et al. Long term persistence of yellow fever neutralising antibodies in elderly persons. Bull. Soc. Pathol. Exot. 104, 260–265 (2011).
16.
Kumar R, Tripathi P, Rizvi A. Effectiveness of one dose of SA 14–14-2 vaccine against Japanese encephalitis. N. Engl. J. Med. 360, 1465–1466 (2009).
17.
Del Angel RM, Reyes-del VJ. Dengue vaccines: strongly sought but not a reality just yet. PLoS Pathog. 9, e1003551 (2013).
18.
Torresi J, Tapia-Conyer R, Margolis H. Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V international meeting. PLoS Negl. Trop. Dis. 7, e2261 (2013).
19.
Züst R, Dong H, Li XF et al. Rational design of a live attenuated dengue vaccine: 2-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques. PLoS Pathog. 9, e1003521 (2013).
20.
Huang CY, Kinney RM, Livengood JA et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl. Trop. Dis. 7, e2243 (2013).
21.
Zhao H, Jiang T, Zhou XZ et al. Induction of neutralizing antibodies against four serotypes of dengue virusesby MixBiEDIII, a tetravalent dengue vaccine. PLoS ONE 9, e86573 (2014).
22.
Dayan GH, Thakur M, Boaz M, Johnson C. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine 31, 5047–5054 (2013).
23.
Dayan GH, Garbes P, Noriega F et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccinein children and adolescents ages 9–16 years in Brazil. Am. J. Trop. Med. Hyg. 89, 1058–1065 (2013).
24.
Sabchareon A, Wallace D, Sirivichayakul C et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomized, con-trolled Phase IIb trial. Lancet 380, 1559–1567 (2012).
25.
Villar LA, Rivera-Medina DM, Arredondo-García JL et al. Safety and immunogenicity of a recombinant tetravalentdengue vaccine in 9–16 year olds. A randomized, controlled, Phase II trial in Latin America. Pediatr. Infect. Dis. J. 32, 1102–1109 (2013).
26.
Leo YS, Wilder-Smith A, Archuleta S et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years-Phase II randomized controlled trial in Singapore. Hum. Vaccines Immunother. 8, 1259–1271 (2012).
27.
Tran NH, Luong CQ, Vu TQH et al. Safety and immuno-genicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J. Vaccines Vaccin. 3, 1–7 (2012).
28.
Lanata CF, Andrade T, Gil AI et al. Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-oldspreviously vaccinated against yellow fever: randomized, controlled, Phase II study in Piura, Peru. Vaccine 30, 5935–5941 (2012).
29.
Amar-Singh HSS, Koh MT, Tan KK et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: a randomized, placebo-controlled Phase III study. Vaccine 31, 5814–5821 (2013).
30.
Capeding MR, Tran NH, Hadinegoro SRS et al. Clinical efficacy and safety of a novel tetravalent dengue in healthy children in Asia: a Phase 3, randomized, observer-masked, placebo-controlled trial. Lancet 384, 1358–1365 (2014).
•• Phase III trials (efficacy) of a dengue vaccine candidate which is included in our meta-analysis.
31.
Villar L, Dayan GH, Arredondo-García JL et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372, 113–123 (2015).
•• Phase III trials (efficacy) of a dengue vaccine candidate which is included in our meta-analysis.
32.
Guy B, Saville M, Lang J et al. Development of Sanofi Pasteur tetravalent dengue vaccine. Rev. Pan-Amaz. Saude. 2, 51–64 (2011).
33.
Coller GBA, Clements DE. Dengue vaccines: progress and challenges. Curr. Opin. Immunol. 23, 391–398 (2011).
34.
Sanofi Pasteur. Dengvaxia®, world's first dengue vaccine, approved in Mexico (2015). www.sanofipasteur.com/en/articles/dengvaxia-world-s-first-dengue-vaccine-approved-in-mexico.aspx.
35.
Sanofi Pasteur. Sanofi Pasteur's dengue vaccine approved in the Philippines (2015). www.sanofipasteur.com/en/articles/sanofi-pasteur-dengue-vaccine-approved-in-the-philippines.aspx.
36.
Sanofi Pasteur. Dengvaxia® first dengue vaccine approved in Brazil (2015). www.sanofipasteur.com/en/articles/Dengvaxia-First-Dengue-Vaccine-Approved-in-Brazil.aspx.
37.
Sanofi Pasteur. Sanofi Pasteur dengue vaccine approved in Costa Rica (2016). www.sanofipasteur.ca/node/49001.
38.
Sanofi Pasteur. First dengue vaccine approved in more than 10 countries (2016). www.sanofipasteur.com/en/Documents/PDF/PR/20161004_First_Dengue_Vaccine_Approved_in_More_than_10_Countries_EN.pdf.
39.
Dengue Vaccine Initiative. Dengue vaccine initiative statement on SAGE dengue vaccine recommendations (2016). www.denguevaccines.org/sites/default/files/DVI%20Statement%20-%20SAGE%20Recommendations%20Dengue%20Vaccines%20April%202016_0.pdf.
40.
European Medicines Agency. Committee for Human Medicinal Products – Guideline on immunogenicity assessment of biotechnology-derived Therapeutic proteins (2007). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf.
41.
WHO. Background paper on dengue vaccines (2016). www.who.int/immunization/sage/meetings/2016/april/1_Background_Paper_Dengue_Vaccines_2016_03_17.pdf.
•• WHO publication that is important to dengue vaccine context.
42.
WHO. Dengue Vaccine: WHO position paper – July 2016. Wkly Epidemiol. Rec., 30, 91, 349–364 (2016). www.who.int/wer/2016/wer9130.pdf?ua=1.
•• WHO publication that is important to dengue vaccine context.
43.
Hadinegoro SR, Arredondo-Garcia JL, Capeding MR et al. Efficacy and long-term safety of dengue vaccine in regions of endemic disease. N. Engl. J. Med. 13, 1195–1206 (2015).
•• Important to complement our knowledge of the disease and of CYD-TDV.
44.
Flashe S, Jit M, Rodrigues-Barraquer et al. Comparative modelling of dengue vaccine public health impact (CMDVI) (2016). www.who.int/immunization/sage/meetings/2016/april/2_CMDVI_Report_FINAL.pdf.
45.
Ferguson NM, Rodríguez-Barraquer I, Dorigatti I. Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment. Science 353(6303), 1033–1036 (2016).
46.
Higgins JPT, Green S (Eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration (2011). www.cochrane-handbook.org.
• Important reference source for conducting meta-analyses.
47.
Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 7, 1–97 (2009).
• Important reference source for conducting meta-analyses.
48.
Mansfield KL, Horton DL, Johnson N et al. Flavivirus-induced antibody cross-reactivity. J. Gen. Virol. 92, 2821–2829 (2011).
49.
Deeks JJ, Higgins J, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (Eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration (2011). www.cochrane-handbook.org.
50.
Higgins JPT, Altman AD, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (Eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration (2011). www.cochrane-handbook.org.
51.
Buddhari D, Aldstadt J, Endy TP et al. Dengue virus neutralizing antibody levels associated with protection from infection in Thai cluster studies Darunee Buddhari. PLoS Negl. Trop. Dis. 8, e3230 (2014).
52.
Guntur F, Thiam-Seng Ng, Victor AK et al. Structural changes in dengue virus when exposed to a temperature of 37°C. J. Virol. 13, 7585–7592 (2013).
53.
Guntur F, Kristie DI, Thiam-Seng Ng et al. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 6243, 88–90 (2015).
54.
Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV induced protection. J. Vector Borne Dis. 14, 45–54 (2016).
55.
WHO. Guidelines for the clinical evaluation of dengue vaccines in endemic areas – immunization, vaccines and biologicals (2008). http://whqlibdoc.who.int/hq/2008/WHO_IVB_08.12_eng.pdf.
•• WHO publications that are important to dengue vaccine context.
56.
US FDA. Office of Vaccines Research and Review Center for Biologics Evaluation and Research. Use of Immunogenicity Data to Assess Vaccine Effectiveness (2013). www.google.com.br/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwjJ8eemiZTQAhXFDpAKHeO_AjsQFggiMAA&url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FBiologicsBloodVaccines%2FNewsEvents%2FWorkshopsMeetingsConferences%2FUCM338945.ppt&usg=AFQjCNH191BGAMd4lpfWf9lwo3TS7Vn2qw.
57.
European Medicines Agency. Committee for Human Medicinal Products - Note for Guidance on the Clinical Evaluation of Vaccines (2005). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003875.pdf.
58.
Roland D, Bisserbe N. Mexico approves Sanofi's dengue vaccine but pricing questions remain. The Wall Street Journal. (2015). www.wsj.com/articles/mexico-approves-sanofis-dengue-vaccine-but-pricing-questions-remain-1449676613.
59.
Leder K, Torresi J, Libman MD. GeoSentinel surveillance of illness in returned travelers, 2007– 2011. Ann. Intern. Med. 19, 456–468 (2013).
60.
Fukusumi M, Arashiro T, Arima Y et al. Dengue Sentinel traveler surveillance: monthly and yearly notification trends among Japanese travelers, 2006–2014. PLoS Negl. Trop. Dis. 10, 1–14 (2016).
61.
Gailhardou S, Skipetrova A, Dayan GH. Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials. PLoS Negl. Trop. Dis. 10, 1–25 (2015).
62.
Vaccine market by technology & types, various classes & indications – global forecasts to 2022. Research and Markets (2013). www.researchandmarkets.com/research/x5nr7d/vaccine_market_by.
63.
Jadhav S, Gautam M, Gairola S. Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices. Clin. Microbiol. Infect. 20, 37–44 (2014).
64.
Dengue Vaccine Initiative. Planning for the introduction of dengue vaccines (2011). www.denguevaccines.org/sites/default/files/ADPB-Brazil_11-Short.pdf.
65.
Secretaria de Saúde do Paraná. Manual de Normas e Procedimentos para vacinação – Dengue (2016). www.saude.pr.gov.br/arquivos/File/VacinaDENGUE_protocolo.pdf.
66.
O DIARIO. Maringa vacinou 190 mil contra Dengue. http://maringa.odiario.com/parana/2016/09/parana-vacinou-190-mil-contra-a-dengue/2247982/.
67.
Brasil. Câmara de Regulação de Preços (CMED) (2016). http://portal.anvisa.gov.br/documents/374947/2829072/LISTA_CONFORMIDADE_GOV_2016–10–20.pdf/20b61fe1-f8a9–41ae-a55d-cb8613953dd8.
68.
BRASIL. Anvisa autoriza Instituto Butantan a iniciar Ensaio Clínico fase 3 da vacina contra dengue (2015). http://portal.anvisa.gov.br/wps/content/anvisa+portal/anvisa/sala+de+imprensa/menu+-+noticias+anos/2015/anvisa+autoriza+instituto+butantan+a+iniciar+ensaio+clinico+fase+3+da+vacina+contra+dengue.
•• Indicates that the vaccine developed by the Butantan Institute (Brazil) gained approval for a Phase III trial, which will probably lead to licensing of the vaccine in Brazil in the coming years.
69.
Bero L, Oostvogel F, Bachetti P, Lee K. Factors associated with findings of published trials of drug–drugs comparisons: why some stations appear more efficacious than others. PLoS Med. 4(6), e184 (2007).
70.
Lexchini J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 1167(326), 1167–1170 (2003).
Information & Authors
Information
Published In
Copyright
© Future Medicine Ltd.
History
Published online: 13 January 2017
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety. (2017) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2016-0045
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Viviana Maria Gianguzzo, Michelangelo Rottura, Federica Maria Sacco, Matthew Gavino Donadu, Giuseppina Sanna, Natasha Irrera, Egidio Imbalzano, Vincenzo Arcoraci, Giuseppinella Melita, Ylenia Marino, Sara Manti, Giovanni Pallio, Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database, Frontiers in Pharmacology, 10.3389/fphar.2026.1789762, 17, (2026).
- Guowei Sun, Ali Mai, Yunfeng Liu, Mosquito control models based on Wolbachia or sterile insect techniques, Discrete and Continuous Dynamical Systems - B, 10.3934/dcdsb.2025160, 33, 0, (464-489), (2026).
- Qian Ding, Jianshe Yu, Zhiming Guo, Yuming Chen, Yunfeng Liu, Periodic dynamics of a general switching dynamical system, European Journal of Applied Mathematics, 10.1017/S0956792525100065, (1-15), (2025).
- Antonio Ferreira Mendes-Sousa, Veruska Cavalcanti Barros, Andressa Barros Ibiapina, Maria Clara Moura Silva, Vagner José Mendonça, Bruno Guedes Alcoforado Aguiar, Elisabeth Biruel, Carmen Verônica Mendes Abdala, Lilian Silva Catenacci, Evidence map of strategies for preventing and controlling Aedes aegypti infestation and related viral infections, Revista Panamericana de Salud Pública, 10.26633/RPSP.2025.63, 49, (1), (2025).
- Jarvis Z. H. Goh, Lachlan De Hayr, Alexander A. Khromykh, Andrii Slonchak, The Flavivirus Non-Structural Protein 5 (NS5): Structure, Functions, and Targeting for Development of Vaccines and Therapeutics, Vaccines, 10.3390/vaccines12080865, 12, 8, (865), (2024).
- Anastasia Latanova, Vadim Karpov, Elizaveta Starodubova, Extracellular Vesicles in Flaviviridae Pathogenesis: Their Roles in Viral Transmission, Immune Evasion, and Inflammation, International Journal of Molecular Sciences, 10.3390/ijms25042144, 25, 4, (2144), (2024).
- Daniel Msellemu, Marcel Tanner, Rajpal Yadav, Sarah J. Moore, Occupational exposure to malaria, leishmaniasis and arbovirus vectors in endemic regions: A systematic review, Current Research in Parasitology & Vector-Borne Diseases, 10.1016/j.crpvbd.2024.100185, 6, (100185), (2024).
- Eveline Bezerra De Souza, Priscila Da Silva Castro, Isabella Piassi Dias-Godói, Maíra Catherine Pereira Turiel Silva, Leticia Dias Lima Jedlicka, TRANSDISCIPLINARIDADE COMO ESTRATÉGIA DE ENSINO E EXTENSÃO EM EDUCAÇÃO EM SAÚDE, Revista Chão da Escola, 10.55823/rce.v19i19.142, 19, (69-81), (2022).
- Camila Lorenz, Francisco Chiaravalloti-Neto, Control methods for Aedes aegypti: Have we lost the battle?, Travel Medicine and Infectious Disease, 10.1016/j.tmaid.2022.102428, 49, (102428), (2022).
- Dawid Pieper, Irma Hellbrecht, Linlu Zhao, Clemens Baur, Georgia Pick, Sarah Schneider, Thomas Harder, Kelsey Young, Andrea C. Tricco, Ella Westhaver, Matthew Tunis, Impact of industry sponsorship on the quality of systematic reviews of vaccines: a cross-sectional analysis of studies published from 2016 to 2019, Systematic Reviews, 10.1186/s13643-022-02051-x, 11, 1, (2022).